



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HAMI 3379

Cat. No.:	HY-112248A		
CAS No.:	1245653-57-9		
Molecular Formula:	C ₃₄ H ₄₅ NO ₈		
Molecular Weight:	595.72		
Target:	Leukotriene Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (167.86 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.6786 mL	8.3932 mL	16.7864 mL
	5 mM		0.3357 mL	1.6786 mL	3.3573 mL
	10 mM		0.1679 mL	0.8393 mL	1.6786 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	HAMI 3379 is a potent and selective CysLT ₂ receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation ^{[1][2]} .
IC ₅₀ & Target	CysLT ₂
In Vitro	In a CysLT₂ receptor reporter cell line, HAMI3379 antagonizes leukotriene D₄- (LTD₄-) and leukotriene C₄- (LTC₄-) induced intracellular calcium mobilization with IC₅₀ values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT₁ receptor cell line (IC₅₀>10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HAMI 3379 (0.025-0.4 mg/kg; ip) with 0.1-0.4 mg/kg significantly reduces the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio^[2]. HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holding angle^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (250-300 g) after MCAO ^[2]
Dosage:	0.025, 0.05, 0.1, 0.2, 0.4 mg/kg
Administration:	IP
Result:	Significantly reduced the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio (an index of brain edema) with 0.1-0.4 mg/kg. Significantly reduced the neurological deficit score.

REFERENCES

- [1]. F Wunder, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT₂) receptor. Br J Pharmacol. 2010 May;160(2):399-409.
- [2]. Q J Shi, et al. HAMI 3379, a CysLT₂R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015 Apr 16;291:53-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA